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Abstract
Background: Interferon gamma is a major macrophage-activating cytokine during infection with Mycobacterium 
tuberculosis, the causative pathogen of tuberculosis, and its role has been well established in animal models and in 
humans. This cytokine is produced by activated T helper 1 cells, which can best deal with intracellular pathogens such 
as M. tuberculosis. Based on the hypothesis that genes which regulate interferon gamma may influence tuberculosis 
susceptibility, we investigated polymorphisms in eight candidate genes.
Methods: Fifty-four polymorphisms in eight candidate genes were genotyped in over 800 tuberculosis cases and 
healthy controls in a population-based case-control association study in a South African population. Genotyping 
methods used included the SNPlex Genotyping System™, capillary electrophoresis of fluorescently labelled PCR 
products, TaqMan® SNP genotyping assays or the amplification mutation refraction system. Single polymorphisms as 
well as haplotypes of the variants were tested for association with TB using statistical analyses.
Results: A haplotype in interleukin 12B was nominally associated with tuberculosis (p = 0.02), but after permutation 
testing, done to assess the significance for the entire analysis, this was not globally significant. In addition a novel allele 
was found for the interleukin 12B D5S2941 microsatellite.
Conclusions: This study highlights the importance of using larger sample sizes when attempting validation of 
previously reported genetic associations. Initial studies may be false positives or may propose a stronger genetic effect 
than subsequently found to be the case.
Background
Infection with the tuberculosis (TB) agent Mycobacte-
rium tuberculosis (M. tuberculosis) and its subsequent
outcomes (active TB, latent infection or clearance of the
bacterium by the pulmonary immune system) are com-
plex traits due to interactions between numerous host
genetic susceptibility factors and the environment. Heri-
tability analyses have shown that an individual's immune
response to TB infection will be regulated by the genetic
background, with an estimated heritability ranging from
36% to 80% [1-6]. Although many of the host genetic fac-
tors involved in TB still remain unidentified, several sus-
ceptibility genes have been repeatedly associated with the
disease in different populations [7,8].
Interferon gamma (IFN-γ) is a member of the inter-
feron family which plays a crucial role in the reaction of
the immune system in resistance to pathogens such as M.
tuberculosis. There has been a great deal of interest in this
cytokine since its discovery, because the macrophage, an
important target cell of IFN-γ, is a fundamental role
player in the immune system. The T helper 1 (Th1) cell
response, which is required to contain M. tuberculosis
infection, is largely characterised by IFN-γ production.
However production of this cytokine alone is not suffi-
cient to protect against disease [9]. Even so, convincing
evidence for its importance in the control of mycobacte-
rial infections has been found in both experimental and
clinical studies. Mice with a disrupted IFN-γ gene (IFNG)
show increased susceptibility to TB [10] and replacement
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Page 2 of 9of the gene into the lung confers resistance [11]. In most
TB patients the production of M. tuberculosis-induced
IFN-γ by peripheral blood mononuclear cells is reduced
at the time of diagnosis [12]. During and after successful
treatment, these levels increase significantly [13]. It is
also known that the IFN-γ concentrations in sputum and
bronchoalveolar lavage fluid can be used as an estimate of
disease activity via a direct correlation [14]. Although
IFN-γ is required for an initial protective Th1 cell
response to M. tuberculosis, the increased production of
this cytokine post-infection is indicative of the risk of
developing active TB. A recent study showed that
macaque monkeys with high IFN-γ levels two months
post infection with M. tuberculosis were more likely to
develop active TB [15] and similar observations have
been made in humans [16,17], perhaps indicating a failed
immune response. Some experimental data have sug-
gested that IFN-γ is a correlate of protective immunity
against TB [18,19], although other studies in humans,
mice and cattle do not support this [20-22]. Humans with
mutations in genes of the interleukin 12/interleukin 23/
IFN-γ axis have an increased susceptibility to even non-
pathogenic mycobacteria and are extremely susceptible
to M. tuberculosis and Salmonella, but not to other bacte-
ria (reviewed by [23]). These mutations are all associated
with the rare human syndrome known as Mendelian sus-
ceptibility to mycobacterial disease (MSMD).
In addition to the experimental and clinical studies dis-
cussed above, genetic association studies have also sug-
gested that IFN-γ is important in protecting against
mycobacterial infection. The functional +874ATT single
nucleotide polymorphism (SNP), a common variant in
the IFNG gene, has been associated with TB in the South
African Coloured population (SAC) [24] and various oth-
ers [25] and even appears to be clinically relevant in spu-
tum conversion in patients [26]. However, since TB is a
complex disease and several genes are involved in its
pathogenesis, it is possible that genes regulating IFN-γ
levels could also contain variants contributing to suscep-
tibility.
Given the clinical and experimental evidence showing a
crucial role of the IFN-γ pathway in host defence against
TB, we investigated eight candidate genes which could
potentially modulate the function of this vital cytokine,
namely interleukin 4 (IL4), interleukin 10 (IL10), interleu-
kin 12B (IL12B), interleukin 12 receptor beta 1
(IL12RB1), interleukin 12 receptor beta 2 (IL12RB2),
interleukin 18 (IL18), wingless-type MMTV integration
site family, member 5A (WNT5A) and frizzled homolog 5
(FZD5). Fifty-four polymorphisms in these genes were
genotyped and evaluated using a case-control association
analysis in the SAC population. We found a novel allele of
the IL12B microsatellite D5S2941 and showed the signifi-
cance of using larger sample sizes when attempting vali-
dation of previously reported genetic associations.
Methods
Study population
This study was carried out in the Cape Town metropoli-
tan area of the Western Cape Province of South Africa,
where TB is endemic and the estimated prevalence of the
human immunodeficiency virus (HIV) among adults is
approximately 2% [27]. The incidence of TB in this prov-
ince was 1005 per 100 000 population during 2007 [28].
All study participants were from the SAC population.
This unique population is a group of mixed ancestry,
which dates back several generations, and has San, Khoi,
Malaysian, African black and European genetic contribu-
tions. In a previous study no evidence of significant popu-
lation stratification was found for this population (p =
0.26) [29]. Informed consent was obtained from all sub-
jects included in this study. Blood samples were collected
with the approval of the Ethics Committee of the Faculty
of Health Sciences, Stellenbosch University (project
number 95/072), and DNA purified by standard methods.
Known HIV positive individuals were excluded from the
study. Patients (n = 432, age in years = 34 ± 14.8, males =
53%) were confirmed as having TB by bacteriological
analyses. Controls (n = 482, age in years = 27 ± 12.3,
males = 23%) were healthy individuals with no history of
TB who live in the same high incidence community as the
patients and were therefore most likely exposed to the
bacterium.
Genotyping
Polymorphisms were selected from the literature (based
on previous associations (Additional file 1) or functional
effects) and dbSNP (Additional file 2). Genotyping of the
54 variants was done by the SNPlex Genotyping System™
(Applied Biosystems), capillary electrophoresis of fluo-
rescently labelled PCR products [30], TaqMan® SNP geno-
typing assays (Applied Biosystems) [31,32] or the
amplification mutation refraction system (ARMS-PCR)
[33].
Statistical analysis
Since the allele frequencies of the polymorphisms analy-
sed in this study were not known for the SAC population
prior to the completion of genotyping and were necessary
for power calculations before starting the experiment, we
estimated from prior data that each SNP would at least
have a minor allele frequency of 5% in our study group.
Given this assumption we had 95% confidence (alpha
error p = 0.05) and 80% power (beta error = 0.2) to detect
an odds ratio of at least 2.15 with the number of samples
available (432 cases and 482 controls). After genotyping,
power calculations were done with the experimentally
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associated with tuberculosis to confirm that we had
enough power to exclude the previously reported genetic
effect sizes in the SAC population. All power calculations
were done with Epi Info 2000 (Centers for disease control
and prevention, USA). Hardy-Weinberg equilibrium was
assessed for all SNPs.
Contingency tables of the distribution of genotypes
between cases and controls were analysed by the chi-
square test or the Fisher's exact test where appropriate.
For the IL12B D5S2941 (rs10631390) microsatellite
marker the number of ATT repeats was determined by
direct counting and plotted as a distribution graph. Since
this graph was bimodal, the alleles were divided into two
subclasses, as previously described [34-36]. The shorter
repeats, with (ATT)7 and (ATT)8, were designated as S
alleles and the longer repeats, with (ATT)9 and (ATT)10,
were designated as L alleles. Prism version 4.02 was used
to calculate p-values for single-point associations (Addi-
tional file 2).
Bonferroni corrections for multiple testing were done
by considering the number of independent linkage dis-
equilibrium (LD) blocks per gene [37]. We determined
twenty-one independent tests and consequently a p-value
of 0.002 was adopted as a threshold for significance. Hap-
lotype frequencies were inferred using the COCAPHASE
program that is part of the UNPHASED suite [38], http://
portal.litbio.org/Registered/Webapp/glue/). Haplotype
blocks were selected with Haploview [39] by considering
LD blocks. Global significance for haplotype analyses
were tested with COCAPHASE and 10 000 permutation
replications were done.
Results and discussion
We genotyped 53 SNPs and 1 short tandem repeat (STR)
in a large collection of SAC TB patients (n = 432) and
controls (n = 482). All variants were in Hardy-Weinberg
equilibrium in the control population. Four SNPs
(rs2070874 in IL4, rs2853639 in IL12B and rs566926 and
rs7622120 in WNT5A) were nominally associated with
disease (p < 0.05), but these were no longer considered to
be statistically significant after adjusting our threshold of
significance (p = 0.002) to correct for multiple tests
(Additional file 2). More importantly, however, our study
did not replicate previously reported associations of IL4,
IL10, IL12B and IL12RB1 polymorphisms with TB (Addi-
tional files 1 and 2).
Polymorphisms in the IL4 promoter could influence the
transcription levels of that gene. Specifically, a functional
SNP (rs2243250, IL-4-C590T), located 589 bp upstream
of the transcriptional site, has been associated with
increased promoter strength, stronger binding of tran-
scription factors and with different levels of IL-4 activity
[40,41], but was not associated with TB in our study. The
CC genotype of this polymorphism was previously asso-
ciated with protection against pulmonary TB in south
India and Russia [42,43], but not in The Gambia [44]. A
possibility is that alternative splicing, and not increased
expression of the IL4 gene, is the actual regulatory mech-
anism in the production of IL-4, since the product of
alternative splicing, namely IL-4δ2, is a competitive
antagonist of IL-4 [45]. Individuals with latent TB infec-
tion, but who remain healthy, have high levels of this vari-
ant mRNA [46]. During chemotherapy, IL-4δ2, but not
IL-4, levels increased in HIV positive and negative
patients with TB [47]. In addition, there is a difference in
the stability of the two IL4 mRNA products in TB
patients, with IL-4 being more stable than IL-4δ2 [48].
Therefore the ratio of IL-4 and IL-4δ2 may play a role in
disease progression, treatment or outcome, rather than
the phenotype "diseased" per se [48]. An example of a
gene involved in response to TB treatment is the vitamin
D receptor gene (VDR). The time taken for an individual
to convert to sputum negativity while receiving TB che-
motherapy could be independently predicted by the VDR
genotype, even though the VDR polymorphisms were not
associated with TB disease [49]. The apparent exclusion
of a significant genetic effect of IL4 in TB susceptibility is
therefore not an indication that the cytokine does not
have a function in TB disease.
The three most frequently investigated polymorphic
variants in IL10 (rs1800872, rs1800871 and rs1800896)
were not associated with TB in our study. These SNPs are
linked and in most cases three haplotypes (CCG, ATA
and CCA) are observed [50]. The haplotypes and individ-
ual SNPs have been shown to correlate with IL-10 pro-
duction, transcriptional activity and nuclear-binding
activity [50-53]. The rs1800896 SNP has previously been
associated with TB in Cambodia [54], Sicily [55] and Tur-
key [56], but not in China [57], The Gambia [58], Malawi
[59], India [60], Spain [61] or Korea [62]. A smaller, sec-
ond study done in Korea found that this polymorphism
was associated with new and recurrent TB [63]. A recent
meta-analysis found no evidence for association between
TB and this SNP [25]. The rs1800872 SNP is in complete
linkage disequilibrium (LD) with rs1800871 and these
SNPs were associated with TB in Korea [62], but not in
The Gambia, Malawi, China, Colombia, Turkey or
Uganda [56-59,64-66]. Since the three-SNP haplotype of
IL10 was previously associated with TB, we also tested
this in the SAC population. In contrast to other studies
[56,65], there was no association evident in our analysis
(Table 1). A four-SNP haplotype previously associated
with TB in Korea [62], consisting of rs1800896,
rs1800871, rs1800872 and rs3024496, was also not associ-
ated with disease in this study (Table 2). Stein et al. found
that a three-SNP haplotype consisting of rs1518111,
rs1554286 and rs1800872 was associated with protection
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ciation study (number of cases = 2010, number of con-
trols = 2346) in Ghana determined that an IL10 haplotype
was in fact associated with tuberculin skin test (TST)
response and not with pulmonary disease [67]. This could
not be tested for in our study.
The IL12B D5S2941 microsatellite (rs10631390), an
(ATT)n repeat in intron 2 of the gene, was previously
associated with TB in the Hong Kong Chinese population
[68]. We identified a novel (ATT)10 allele (which was con-
firmed by sequencing, data not shown) as well as the
known (ATT)7, (ATT)8 and (ATT)9 alleles of the D5S2941
microsatellite in the SAC population. However, none of
these were associated with TB in our study (Additional
file 2). In previous studies done in Caucasian-Americans
[69] and Hong Kong Chinese [68], only the (ATT)8 and
(ATT)9 alleles of this STR were ever observed, although
the presence of the (ATT)7 allele in two Swedish families
was mentioned in a diabetes study [30]. There are no
reports concerning this marker in African populations.
Since the (ATT)7, (ATT)8 and (ATT)9 alleles were previ-
ously identified in individuals from European and Asian
descent, we speculate that the (ATT)10 allele is a genetic
contribution from the African parental population of the
SAC. The 3'UTR IL12B SNP (rs3212227) [70,71] may
influence gene expression levels and has previously been
associated with TB in various populations [68,72-74], but
not in all [60,75,76]. This polymorphism was not associ-
ated with TB in our study either. Even though none of the
other IL12B polymorphisms investigated were associated
with TB in the single-point analysis (similar to the results
published by Kusuhara et al. [77] for rs11135058,
rs2288831 and rs6870828), we found a nominally signifi-
cant association between a haplotype in IL12B and resis-
tance to TB in the SAC population (Figure 1, Table 3).
The haplotype occurred more frequently in controls than
in cases (p = 0.02, OR = 1.53, 95%CI [1.07-2.02]) and was
tagged by the A allele of the rs2853696 SNP, which was
Table 1: IL10 three SNP haplotype analysis.
Block 1a Frequency Cases Frequency Controls p value
1 C-C-A 0.37 0.34 0.10
2 A-T-A 0.31 0.34 0.08
3 C-C-G 0.32 0.32 0.92
Global significanceb 0.15
a The order of the SNPs is rs1800872, rs1800871 and rs1800896.
b Global significance were calculated in COCAPHASE [38] and 10 000 permutations were done.
Table 2: IL10 four SNP haplotype analysis.
Block 1a Frequency Cases Frequency Controls p value
1 T-A-T-A 0.31 0.34 0.12
2 C-C-C-G 0.29 0.29 0.91
3 C-C-C-A 0.20 0.18 0.18
4 T-C-C-A 0.17 0.16 0.36
5 T-C-C-G 0.03 0.03 0.81
Global significanceb 0.44
a The order of the SNPs is rs3024496, rs1800872, rs1800871, rs1800896.
b Global significance were calculated in COCAPHASE [38] and 10 000 permutations were done.
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tation testing this association was not globally significant
(p = 0.11).
Akahoshi et al. [78] reported the first case-control asso-
ciation study assessing IL12RB1 in TB susceptibility in
the general population. Two common haplotypes (con-
sisting of 4 SNPs, of which rs375947 was genotyped in
our study) were identified, and homozygosity for the
allele 2 haplotype was significantly associated with TB in
Japan. Healthy subjects with this haplotype had lower lev-
els of IL-12-induced signalling. Remus et al. [79] investi-
gated IL12RB1 in 101 Moroccan families where two
promoter polymorphisms in strong LD with each other
(rs436857 and rs393548) were associated with disease,
but no association was detected with the haplotype
reported by Akahoshi et al. [78]. A second study done in
Japan showed that two intronic SNPs were associated
with disease, and a haplotype consisting of different SNPs
to that identified by Akahoshi et al., was associated with
resistance to TB [77]. However, this study did not repli-
cate the association found with the promoter polymor-
phisms in the Moroccan families. Our investigation of the
SAC population, genotyping larger sample sizes than the
two positive reports from Japan [77,78], did not detect
any association with IL12RB1 SNPs (Additional file 2) or
haplotypes (data not shown). Studies in Korea [80] and
Indonesia [81] could not validate the findings either. The
association found in Japan could be population-specific,
but it could also a false-positive result. For this reason,
replication of those results should be attempted in an
independent, larger Asian population [81].
Promoter polymorphisms in IL12RB2 were also investi-
gated, since this gene was previously associated with lep-
rosy [82], an infectious disease caused by Mycobacterium
leprae. Coding SNPs in this gene were previously shown
to have no influence on mycobacterial infection [78,80],
but the degree of expression of this gene, possibly regu-
lated by promoter polymorphisms, could determine the
intensity of the cell-mediated immune response to myco-
bacteria [82]. However rs3762317, which disrupts a
GATA transcription factor binding site [33], and
rs11576006, which participates in the creation of another
GATA site [33], were not associated with TB in our study.
IL-18 is a proinflammatory cytokine and, together with
IL-12, one of the primary inducers of IFN-γ production
by T cells [83,84]. To date only one other association
study between polymorphisms in IL18 and susceptibility
to TB has been published, namely a study by Kusuhara et
Figure 1 Plot of LD between IL12B markers analysed in control in-
dividuals of the SAC population. Generated by Haploview v4.1. The 
5' and 3' ends of the genes are indicated and r2 values (%) are shown 
on the squares (no value = 100%). The colours of the squares represent 
D' values, with dark grey being D' = 1, and white D' = 0.
Table 3: Haplotype analysis of IL12B.
Block 1a Frequency Cases Frequency Controls p value
1 A-G-T-S-G-G 0.63 0.62 0.61
2 C-G-C-L-T-C 0.25 0.24 0.49
3 A-A-T-S-G-G 0.06 0.09 0.02
4 C-G-C-L-T-G 0.03 0.04 0.38
Global significanceb 0.11
a The order of the SNPs in each block corresponds to Figure 1, with D5S2941 included and rs3213096 excluded due to its low allele frequency 
in the SAC population.
b Global significance were calculated in COCAPHASE [38] and 10 000 permutations were done.
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[77]. Amongst others, they genotyped 6 SNPs spread
throughout IL18, but did not consider the functional pro-
moter or synonymous polymorphisms, and found no
association between this gene and TB susceptibility. We
genotyped functional promoter polymorphisms, the syn-
onymous SNP and other variants, but did not detect sta-
tistically significant associations in single SNP or
haplotype analyses either.
Both the innate and acquired immune systems are nec-
essary to eradicate mycobacteria from the host [20]. A
microarray-based gene-expression screening of mycobac-
teria-infected macrophages was done to search for novel
regulatory pathways in innate responses to infection [85].
This study suggested that the Wingless/Frizzled (WNT/
FZD) signalling system connects the innate and adaptive
immunity during infections and implicated the WNT5A
protein in human defence against infection with M.
tuberculosis [85]. Blumenthal et al. [85] demonstrated
that WNT5A is expressed by antigen-presenting cells
when they are stimulated by mycobacteria or other bacte-
rial structures. In addition, both WNT5A and its receptor
FZD5, regulate IL-12 and IFN-γ production in antigen-
presenting cells when exposed to mycobacteria. None of
the WNT5A or FZD5 SNPs genotyped was associated
with disease in the case-control. In addition, no haplo-
types from these genes were associated with TB either.
Perhaps surprisingly, our study did not validate some
previously described findings, even though it had enough
power to detect the effect sizes reported by those studies
(Additional file 2). Some of those associations were based
on extremely low sample numbers (which could lead to
false positive associations) or did not correct for multiple
testing. Underpowered studies may not detect effect sizes
that are small, but reasonable considering the current
understanding of the host genetics of complex diseases
[86]. The question of correcting for multiple tests (and
which method to use) is a contentious one [87] and it is
often bypassed. However, the lack of reproducibility of
certain associations could also be a result of ethnic-spe-
cific associations. Alternatively, polymorphisms could
have smaller effect sizes in the SAC population than we
were able to detect with our sample (see Statistical Analy-
sis and Additional file 2). It is also probable that the poly-
morphisms studied here are associated with primary
infection in the SAC population, a hypothesis which we
would not be able to test due to the high incidence of
latent TB infection in the control community where sam-
ple collection was done. Our study was more likely to test
the possible associations of the SNPs with TB progression
from latent infection to active disease only, but we cannot
rule out the possibility that some controls were not TST
positive as TSTs were not done. However, our previous
study of healthy children and young adults from the con-
trol community found that 80% of children older than 15
years had positive tuberculin skin tests, an indication of
latent infection with M. tuberculosis [88].
The findings presented here demonstrate the common
phenomenon in association studies, where the first report
is usually a positive association and subsequent studies
are often negative. Unfortunately, because of publication
bias, other association studies which considered these
eight candidate genes and found results similar to ours
may not have been published.
Conclusions
We found a nominally significant association with an
IL12B haplotype which was not considered to be globally
significant after permutation testing to determine the sig-
nificance for the entire analysis, and we identified a novel
allele of the IL12B D5S2941 microsatellite in the SAC
population. This research illustrates the complexity of TB
where a well-known pathway cannot be conclusively
genetically associated with the disease.
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